Stockreport

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentia [Read more]